Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product, Qutenza (capsaicin)

Shots:

• Grunenthal acquired Averitas Pharma in all stocks transaction, gained the commercialization rights for Qutenza
• The focus of the acquisition is to expand and strengthen its footprints in the markets of US
• Qutenza (8% capsaicin) is an analgesic and is approved by the US FDA & EU for postherpetic neuralgia (PHN) & peripheral neuropathic pain indication in adults respectively

Click here to read full press release/ article | Ref: Grunenthal | Image: Glarus24